Benefits of Cytori’s Cell Therapy for Hand Function of Scleroderma Patients

0
(0)

SCLhand

Late stage cell therapy developer Cytori Therapeutics, a company creating autologous cell therapies from adipose tissue to treat a variety of medical conditions, recently published its findings from a 12-month clinical follow-up of scleroderma patients who were enrolled in the Scleradec-I clinical trial on hand dysfunction associated with the disease. The Scleradec-I study, an investigator-initiated, open-label 12 patient trial, was led by Dr. Brigitte Granel and Dr. Guy Magalon from the Assistance Publique des Hôpitaux de Marseille. The manuscript, titled, “Autologous adipose-derived stromal vascular fraction in patients with systemic sclerosis: 12-month follow-up” was published in the journal Rheumatology.

Learn about the benefits of Cytori’s cell therapy here: http://bit.ly/1Slm3yc

Keep updated on all the latest scleroderma news here: http://bit.ly/20sZaNS

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Leave a Comment

Your email address will not be published. Required fields are marked *